What is KinDex Pharmaceuticals?

KinDex was established in the fall of 2009 to focus on the discovery and development of molecules that modulate key regulatory networks associated with chronic disease

Kindex Lab

The principal targets for KinDex are the regulatory nodes embedded in signaling networks that control genetic expression patterns associated with insulin resistance, Type 2 diabetes, cardio-metabolic syndrome and obesity. KinDex has a portfolio of lead molecules that have demonstrated a novel mechanism of action in their ability to safely normalize the disturbed regulatory networks related to the etiology of Type 2 diabetes and obesity.


our pipeline

KinDex’s molecules have demonstrated efficacy in in vitro and in vivo models of diabetes and inflammation. We have successfully completed Phase 1 safety studies of our most advanced drug candidate and anticipate initiating proof-of-concept efficacy studies in diabetic patients in the near future.

Diabetes constitutes a group of metabolic diseases characterized by high blood glucose levels and an inability to produce or utilize insulin. In the U.S., almost 19 million people, or over 8% of the general population, have been diagnosed with diabetes. Another 7 million people have diabetes but have not yet been diagnosed, while approximately 80 million people are estimated to have prediabetes. Diabetes is a recognized contributing cause of heart disease, high blood pressure, blindness, kidney disease, neuropathy and lower-limb amputations. In 20071, the latest year for which data are available, diabetes was responsible for or contributed to over 230,000 deaths in the U.S.

12011 National Diabetes Fact Sheet

various graphics
2014 Kindex Pharmaceuticals, 800 Fifth Avenue, Suite 4100
Seattle, WA 98104
206-922-2912
Website by Big Step Consulting